Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of ...

Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...

Hims & Hers stock fell sharply on Monday after the FDA said it would take steps to restrict the sale of its compounded ...

Hims & Hers Health shares plunged Monday after the telehealth company said it would stop selling its compounded weight-loss ...

Everyone's ganging up on Hims & Hers stock this week.

The three-day rout was driven by Novo Nordisk’s lawsuit and an FDA crackdown on compounded GLP-1 drugs. ・Deutsche Bank and ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.5, a high estimate of $60.00 ...

By Nell Mackenzie and Samuel Indyk LONDON, Feb 13 (Reuters) - Hedge fund bets against Hims & Hers Health hit their highest in ...

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA ...

Hims & Hers Health faces slowing revenue/subscriber growth, premium valuation and regulatory risk from copycat obesity drugs. Learn more about HIMS stock here.

NEW YORK, Feb 6 (Reuters) - Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its ...